This recent transaction increases Tim Ocain’s holding in the company by 32.64% to a total of $617.8K.
ENTA’s market cap is $1.59B and the company has a P/E ratio of 21.90. Currently, Enanta Pharmaceuticals has an average volume of 378.8K.
Based on 3 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $100.33, reflecting a 32.0% upside.
The insider sentiment on Enanta Pharmaceuticals has been positive according to 28 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. Its brands include Mavyret and Viekira Pak.